Quick Answer
Intellia Therapeutics, Inc. reported Operating Income Loss of -$440.99 million for the year ending 2025.
- Intellia Therapeutics, Inc. showed an increase of +17.5% in Operating Income Loss from 2024 to 2025.
- This data is from Intellia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$1.20 million | Q2 2015: -$3.42 million | Q3 2015: -$3.30 million | Q4 2015: -$5.49 million | Q1 2016: -$6.69 million | Q2 2016: -$6.95 million | Q3 2016: -$7.70 million | Q4 2016: -$10.82 million | Q1 2017: -$12.95 million | Q2 2017: -$16.02 million | Q3 2017: -$15.88 million | Q4 2017: -$24.72 million | Q1 2018: -$22.43 million | Q2 2018: -$23.60 million | Q3 2018: -$24.10 million | Q4 2018: -$20.75 million | Q1 2019: -$23.81 million | Q2 2019: -$27.46 million | Q3 2019: -$25.33 million | Q4 2019: -$29.77 million | Q1 2020: -$33.05 million | Q2 2020: -$33.03 million | Q3 2020: -$28.10 million | Q4 2020: -$42.40 million | Q1 2021: -$46.43 million | Q2 2021: -$69.02 million | Q3 2021: -$71.99 million | Q1 2022: -$144.25 million | Q2 2022: -$98.30 million | Q3 2022: -$105.53 million | Q1 2023: -$111.96 million | Q2 2023: -$132.33 million | Q3 2023: -$131.11 million | Q1 2024: -$114.00 million | Q2 2024: -$139.04 million | Q3 2024: -$144.77 million | Q1 2025: -$120.81 million | Q2 2025: -$110.00 million | Q3 2025: -$111.48 million.
- Over the full 11 years of available data (2015 to 2025), Intellia Therapeutics, Inc.'s Operating Income Loss has declined by 3,188.8%.
- Historical annual values: Fiscal year 2025: -$440.99 million | Fiscal year 2024: -$534.26 million | Fiscal year 2023: -$515.29 million | Fiscal year 2022: -$458.16 million | Fiscal year 2021: -$267.85 million | Fiscal year 2020: -$136.58 million | Fiscal year 2019: -$106.37 million | Fiscal year 2018: -$90.87 million | Fiscal year 2017: -$69.56 million | Fiscal year 2016: -$32.16 million | Fiscal year 2015: -$13.41 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: